Healthy
Conditions
Brief summary
Investigation of the bioavailability of linagliptin after concomitant multiple oral administration of 5 mg linagliptin tablets and 600 mg rifampicin (Treatment A) in comparison to multiple oral administration of 5 mg linagliptin tablets given alone (Treatment B)
Interventions
DRUGRifampicin
DRUGLinagliptin
Sponsors
Boehringer Ingelheim
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests * Age 18 to 50 years (incl.) * BMI 18.5 to 29.9 kg/m2 (incl.) * Signed and dated written informed consent prior to admission to the study in accordance with Good clinical practice (GCP) and the local legislation
Exclusion criteria
* Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance * Any evidence of a clinically relevant concomitant disease * Gastrointestinal, hepatic (incl. porphyrias), renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Surgery of the gastrointestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History of relevant orthostatic hypotension, fainting spells or blackouts. * Chronic or relevant acute infections * History of relevant allergy or hypersensitivity (including allergy to drug or its excipients) * Intake of drugs with a long half-life (more than 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial * Participation in another trial with an investigational drug within two months prior to administration or during the trial * Smoker (more than 10 cigarettes or more than 3 cigars or more than 3 pipes/day) * Inability to refrain from smoking on trial days * Alcohol abuse (more than 30 g/day if male, more than 20 g/day if female) * Drug abuse * Blood donation (more than 100 mL within four weeks prior to administration or during the trial) * Excessive physical activities (within one week prior to administration or during the trial) * Any laboratory value outside the reference range that is of clinical relevance * Inability to comply with dietary regimen of trial site * Thrombocytopenia or increased liver function tests (i.e. Alanine transaminase (ALT), Aspartate transaminase (AST), bilirubin, Alkaline phosphatase (AP), Gamma-glutamyl transferase (GGT)) at screening * prior rifampicin exposure For female subjects: * Positive pregnancy test, pregnancy or planning to become pregnant during the study or within 2 months after study completion * No adequate contraception during the study and until 1 month after study completion, i.e. not any of the following: IUD (intrauterine device), sexual abstinence for at least 1 month prior to enrolment, vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (including hysterectomy). Females, who do not have a vasectomised partner, are not sexually abstinent or surgically sterile have to use an additional barrier method (e.g. condom, diaphragm with spermicide) * Lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the steady state concentration-time curve of linagliptin in plasma (AUCτ,ss) | up to 19 days |
| Maximum measured steady state concentration of linagliptin in plasma (Cmax,ss) | up to 19 days |
Secondary
| Measure | Time frame |
|---|---|
| AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) of CD 1790 | up to 19 days |
| Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of CD 1790 | up to 19 days |
| Ratio of urinary concentrations of 6β-hydroxycortisol to cortisol | screening, days 1 and 6 of treatment A, days 4, 6, 8 and 12 of treatment B always in the morning before drug administration |
| fet1-t2,ss ( fraction of administered drug excreted unchanged in urine at steady state over the respective time interval, where t1 and t2 define beginning and end times of the time interval) of linagliptin | up to 19 days |
| Number of patients with adverse events | up to 42 days |
| Aet1-t2,ss ( amount of analyte that is eliminated in urine from the time point t1 to time point t2 under steady state conditions) of linagliptin | up to 19 days |
| Number of patients with abnormal findings in physical examination | up to 21 days after last drug administration |
| Number of patients with abnormal changes in laboratory parameters | up to 21 days after last drug administration |
| Number of patients with clinically significant changes in Vital signs (Blood Pressure (BP), Pulse Rate (PR)) | up to 21 days after last drug administration |
| Number of patients with clinically significant changes in 12-lead ECG (electrocardiogram) | up to 21 days after last drug administration |
| Assessment of global tolerability by investigator on a 4-point scale | up to 21 days after last drug administration |
| Dipeptidyl-peptidase 4 (DPP-4) inhibition | up to 19 days |
Outcome results
None listed